Athira Pharma, Inc. (ATHA)

USD 0.25

(-0.04%)

Market Cap (In USD)

9.75 Million

Revenue (In USD)

-

Net Income (In USD)

-117.67 Million

Avg. Volume

202.93 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
0.412-4.298
PE
-0.1
EPS
-2.52
Beta Value
2.835
ISIN
US04746L1044
CUSIP
04746L104
CIK
1620463
Shares
39042400.0
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Mark J. Litton M.B.A., Ph.D.
Employee Count
-
Website
https://www.athira.com
Ipo Date
2020-09-18
Details
Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease. It also develops product candidates, which are in preclinical stage, including ATH-1019 for peripheral nervous system indications; and ATH-1020 for neuropsychiatric conditions. Athira Pharma, Inc. was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. The company was incorporated in 2011 and is headquartered in Bothell, Washington.